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ABSTRACT
MicroRNAs (miRNAs) are often deregulated in can-
cer and are thought to play an important role in can-
cer development. Large amount of differentially ex-
pressed miRNAs have been identified in various can-
cers by using high-throughput methods. It is there-
fore quite important to make a comprehensive col-
lection of these miRNAs and to decipher their roles
in oncogenesis and tumor progression. In 2010, we
presented the first release of dbDEMC, represent-
ing a database for collection of differentially ex-
pressed miRNAs in human cancers obtained from
microarray data. Here we describe an update of the
database. dbDEMC 2.0 documents 209 expression
profiling data sets across 36 cancer types and 73
subtypes, and a total of 2224 differentially expressed
miRNAs were identified. An easy-to-use web inter-
face was constructed that allows users to make a
quick search of the differentially expressed miRNAs
in certain cancer types. In addition, a new func-
tion of ‘meta-profiling’ was added to view differential
expression events according to user-defined miR-
NAs and cancer types. We expect this database to
continue to serve as a valuable source for cancer
investigation and potential clinical application re-
lated to miRNAs. dbDEMC 2.0 is freely available at
http://www.picb.ac.cn/dbDEMC.
INTRODUCTION
As the leading cause of human death, cancer continues to
represent a huge economic and social burden to society.
It currently accounts for >8 million deaths according to
World Cancer Report 2014 (1), and the incidence and mor-
tality rates of many cancer types have been increasing over
the last years. It is therefore urgent to understand themolec-
ular mechanisms underlying cancer development and to de-
velop reliable biomarkers for early detection, diagnosis and
treatment of cancer.
In recent years, large numbers of studies have indicated
that microRNAs (miRNAs), a class of small noncoding
RNAs (∼18–23 nt in length), are highly associated with ini-
tiation and progression of cancer.MiRNAsmainly function
to regulate mRNA expression through sequence specific in-
teraction with 3’-untranslated regions (3’-UTRs) (2,3). To
date, more than 2500 miRNAs have been identified in the
human genome according to latest release of miRBase (4).
Studies have indicated that miRNAs play important roles
in a wide range of physiological and biological processes,
such as: cell division, proliferation, differentiation, develop-
ment, metabolism and apoptosis (5–8). Hence, many miR-
NAs could function as oncogenes or tumor suppressors
by regulating different cancer associated genes. Over the
last decade, associations between alterations in miRNA ex-
pression and the occurrence of cancer has been the sub-
ject of intense investigation (9). MiRNAs have emerged as
an important kind of diagnostic, prognostic and predic-
tive biomarker for different types of cancer, and earned a
promising role for cancer biology (10,11). In addition, miR-
NAs offer potential new avenues for cancer treatment, for
instance by using miRNA mimics or antogomirs (12,13).
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In the past years, genome wide detection methods in-
cluding microarray and next generation sequencing have
been developed to identify miRNA profiles in a variety
of cancer types (14,15). Huge amount of miRNA expres-
sion profiling data for cancers was released by public re-
sources, such as the Gene Expression Omnibus (GEO) and
other cancer projects including The Cancer Genome At-
las (TCGA), and the International Cancer Genome Con-
sortium (ICGC). These valuable resources provide an op-
portunity to investigate cancer associated miRNAs from
large amount of samples. However, these miRNA–cancer
relationships are buried in thousands of published studies.
It is still a challenging task to translate this huge amount
of miRNA expression data into a systematically annotated
and documented database for ease of interpretation.
Previously, we developed dbDEMC (16), a database of
miRNA expression changes in different cancer types. It
differs from other databases that used mainly manually
collection or text mining methods, such as miR2Disease
(17), HMDD (18), miR2cancer (19), TUMIR (20) or On-
comiRDB (21), to identify cancer associated miRNAs, in
that dbDEMC identifies these differentially expressed miR-
NAs from de-novo analysis of high-throughput expression
data. The first version of dbDEMC provides researchers an
easy to use resource to retrieve cancer related miRNAs in
fourteen cancer types. Each miRNA entry provides differ-
ential expression pattern seen in these cancer types, and also
the annotation from different experiments. Since its first re-
lease in 2010, many more cancer miRNA expression profil-
ing studies have been published. It is therefore paramount
to update the database to keep a pace with the rate of data
accrual. Here we introduce dbDEMC 2.0, an updated and
significantly expanded version of this database. The sec-
ond version of dbDEMC documents a total of 2224 differ-
entially expressed miRNAs from 36 cancer types through
the processing of >200 expression data sets. In addition to
the expanded data volume, the search and browser func-
tions are retained and enhanced, and new features have been
added for better usage of the database. We expect this up-
dated database could facilitate the identification of cancer
associated miRNAs and benefit the investigation of their
roles in physiological and pathological processes of cancer
development. All the information in dbDEMC 2.0 is freely
available to the public domain through http://www.picb.ac.
cn/dbDEMC.
DATA COLLECTION AND PROCESSING
We conducted a systematic data search for cancer related
miRNA expression profiles by using cancer-related key-
words, such as: ‘cancer’, ‘tumor’, ‘carcinoma’ and ‘neo-
plasm’, in combination with ‘microRNA’ or ‘miRNA’ from
GEO. All the data sets used are limited to human studies
published before June 2016. In addition, we also collected
high quality miRNA expression profiles for 22 cancer types
generated bymiRNA-seq from TCGA.More than 400 data
sets were collected initially. The data processing procedure
is as follows:
i. For data quality control, wemade a rigorousmanual re-
view for each data set to screen those meeting the aim of
this study initially. To ensure that only high quality data
sets were included in our database, only the data sets
have enough samples for both case and control (at least
three) groups were used. After this quality control step,
a total of 209 miRNA expression data sets remained.
ii. For each dataset, the expression values were logarith-
mically transformed (base 2) and quantile normalized.
For miRNA expression data sets get from TCGA, we
usedmiRNA isoforms expression data as it provides the
mature miRNA expression information. The maximum
expression value was selected if there were multiple iso-
forms for a given miRNA in each sample. The limma
(Linear Models for Microarray and RNA-seq Data)
package (22) embedded inR (http://www.r-project.org/)
was used to selectmiRNAswhosemean expression level
is significantly different between case and control sam-
ples. The population level control and one factor anal-
ysis were used. Those miRNAs with FDR adjusted P-
value <0.05 were extracted as candidates that have sig-
nificant different expression.
iii. The inconsistency of the miRNA name annotated in
different updates from miRBase could result in ambi-
guities for the miRNA names from different expres-
sion platforms. To overcome this problem, we used
miRBase-tracker (23) to unify all the miRNA names to
those annotated in the most recent release of the miR-
Base. In addition, the miRNA IDs were also uniformly
mapped to the HUGO Gene Nomenclature Commit-
tee (HGNC) (24), Entrez Gene ID (25) and Ensemble
Gene ID (26). The sequences for mature and precur-
sor miRNAs from miRBase were integrated. Further-
more, the cancer names were also unified into 36 differ-
ent cancer tissues: for example, ‘lung squamous cell car-
cinoma’, ‘lung adenocarcinoma’, ‘small cell lung can-
cer’ and ‘large cell lung cancer’ were grouped into the
‘lung cancer’, but decimated by the ‘cancer subtype’.
iv. In addition to the miRNA expression data generated
frommicroarray andmiRNA-seq, low-throughput data
in the original articles such as real-time PCR and north-
ern blot, etc. were manually collected. These types of
information were also integrated into database as vali-
dation of results obtained from high-throughput meth-
ods and represented separately in the database. The
flowchart for data collection and database construction
is shown in Supplementary Figure S1.
DATABASE CONSTRUCTION
For dbDEMC 2.0, all the data are managed by a relational
database implemented with MySQL. The dynamic web in-
terface was developed using PHP and JavaScript. The data
processing and the tool modules implementation for the
database were implemented by in-house R scripts. Apache
was used for the http server.
DATABASE CONTENTS
In this current release, dbDEMC documents 209 miRNA
expression data sets from 143 peer-reviewed publications
and also those from TCGA (Supplementary Table S1). It
now contains 49 202 miRNA–cancer associations for 2224
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differentially expressed miRNAs identified from 436 exper-
iments, and a total of 36 cancer types and 73 cancer sub-
types were covered (Supplementary Table S2). The number
of differentially expressed miRNAs in this version accounts
for 86% of the miRNAs identified in the human genome
(miRBase Release 21). Figure 1A illustrates the number of
differentially expressed miRNAs for each cancer type. Take
the colon cancer, the one with highest number of miRNAs,
as an example, a total of 2116 miRNAs were identified to
be differentially expressed, among which 1116 are upregu-
lated and 1000 are downregulated. In addition, gastric can-
cer and pancreatic cancer are also among the top ranked
cancer types. The number of miRNAs identified for breast
cancer, esophageal cancer, lung cancer and hepatocellular
carcinoma are also increased dramatically over the first re-
lease. The number of differentially expressed miRNAs that
validated by low-throughput methods across major cancer
types is depicted as Figure 1B, brain cancer, colon cancer
and breast cancer are top ranked cancer types.
NEW FEATURES AND DATABASE UTILITY
Improved experimental description
For each of the microarray data sets presented, we reviewed
the samples profiled and classified the experiments for dif-
ferential expression as one of the following categories: can-
cer versus respective normal tissue, high grade cancer ver-
sus low grade cancer, metastasis versus primary cancer, sub-
type1 versus subtype2 (include histological subtypes com-
parison or molecular subtypes comparison), poor outcome
versus good outcome (includes recurrence versus nonre-
currence, long-term versus short-term survival and caner-
specific death versus alive), blood samples from cancer pa-
tient versus blood samples from normal person, and also
drug-treatment versus non-treatment sample. After the as-
signment of samples to different classes, each miRNA was
assessed for differential expression with the limma package.
For each experiment, a detail information page was con-
structed to delineate the related publication reference, GEO
expression profile description, experimental design, cancer
type and subtypes, sample information, miRNA quantifi-
cation procedure and the total number of miRNAs identi-
fied. The percentage of top ranked cancer types for all the
experiments was depicted as Figure 1C, the breast cancer
constitute the largest part of 13% of the total experiments,
then followed by lung cancer and kidney cancer. Whereas
for the experimental design, cancer vs. normal comparison
and high grade versus low grade comparison account for
the most of the total experiments (Figure 1D).
Database query and searching tools
We provide several ways to allow database query. First,
users can perform a quick search in dbDEMC 2.0 by us-
ing miRNA names from the ‘Search’ page (Figure 2A). By
imputing the interested miRNA name in the textbox as the
keyword, the search engine will search all the items that con-
tain the query miRNA in database. The search result page
briefly lists the associated GEO ID, cancer types, subtype,
experimental design, and log FoldChange between case and
control samples (Figure 2B). Multiple miRNAs can be sub-
mitted at a time. Secondly, we also provide the sequence sim-
ilarity search tools implemented by using BLAST, which al-
low user to determine whether an unknownmiRNA is over-
lapped with the existing miRNAs by using the miRNA se-
quence. In addition, users can also select particular cancer
type or subtype and browse all related experiments from the
‘Browse’ page (Figure 2C). The experiment ID, experimen-
tal design, case sample, control sample and the number of
upregulated and downregulatedmiRNAswill be listed (Fig-
ure 2D). After the experiment list obtained, users can select
particular experiment and click the ‘view miRNAs’ button
to navigate the differentially expressed miRNA list.
Enhanced miRNA page
By clicking the hyperlink of a particular miRNA ID, users
can view the detailed expression information of a specific
miRNA (Figure 2E). In this updated version, the detailed
expression information page has also been enhanced. This
page mainly consists of four sections: miRNA Summary,
Expression Profile and Expression Detail and Validation.
In the ‘Summary’ section, miRNA ID, miRBase acces-
sion number, sequences for both mature miRNA and the
precursor miRNA are listed. The hyperlinks to external
databases including HUGO, Entrez gene and Eensembl
are provided, In addition, this page also provides the
links to predicted miRNA target databases including Tar-
getScan (27), DIANA-microT-CDS (28) and RNA22v2
(29). The ‘Expression Profile’ section demonstrates six dif-
ferent heatmaps of the differential expression profile across
six types of the experimental design. The heatmap indicates
the number of experiments to support the conclusion of up-
regulation and downregulation in each cancer type. Here,
the expression profiling heatmap for drug treatment sam-
ples analysis were not included due to the heterogeneity of
different studies, such as different small molecule or vari-
ous experimental conditions used. In the ‘Expression De-
tail’ section, a list of experiment ID, cancer types and sub-
types, experimental design and the differential expression
results getting from limma, such as the log Fold Change,
t-statistics, P-value, FDR adjusted P-value, profiles of the
miRNA were displayed so that the degree of deregulated
information can be evaluated. In the ‘Validation’ section,
the expression information for this miRNA retrieved from
low-throughput experiments were presented if it is available.
Meta-profiling tool
dbDEMC 2.0 adds a new function of meta-profiling that al-
low users to draw differential expression profile for user de-
fined miRNAs among a specific set of cancer types. Users
can input a list of miRNAs, pick one of the six types of ex-
perimental designs and select the cancer types of interested
(Figure 3A). The meta-profiling tool will return a heatmap
depicting the expression change for queriedmiRNAs across
multiple cancer types (Figure 3B). The up- and downregu-
lated expression status is represented by red and green col-
ors according to a confidence score’, that is calculated as
the number of studies on certain types of cancer and exper-
imental design supporting the differential expression status.
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Figure 1. Data content in dbDEMC2.0. (A) Number of DEMs in each cancer types identified by high-throughputmethods. (B) Number of DEMs inmajor
cancer types identified by low-throughput methods. (C) The percentage of experiment data sets in major cancer types. (D) The percentage of experiment
data sets in seven types of experimental design.
This meta-profiling tool helps users to make a quick view of
differential expression events of miRNAs from user defined
cancer types.
COMPARISON TO RELATED DATABASES
Here we compared the content of dbDEMC 2.0 with
cancer related databases including miR2Disease, TUMIR,
HMDD, which are now available to download. We only se-
lected the cancer associated miRNAs, then we unified the
miRNA and cancer names for each database respectively.
The Venn diagram for the cancer related miRNAs indicated
that a great portion of the differentially expressed miR-
NAs in the dbDEMC 2.0 are newly identified, with ∼27%
of miRNAs shared with those of other external databases
(Figure 3C). Whereas for the cancer types, 29 cancer types
overlap with external databases, and seven cancers are not
included by other databases (Figure 3D). This indicates db-
DEMC 2.0 will be an important complement to other sim-
ilar resources.
DISCUSSION
MiRNAs are widely involved in regulation of crucial sig-
naling pathways by controlling the expression of impor-
tant oncogenes in normal cells. Many studies have shown
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Figure 2. A schematic workflow of dbDEMC 2.0. (A) Search page. miRNAs can be searched via miRBase ID, multiple miRNAs input is allowed. (B)
miRNA list page. The page summarizes the search result that matched miRNAs in the database. (C) Browse page. Users can browse experiment list by
selecting particular cancer type or subtype. (D) Experiment list page. The page summarizes the browse result that for cancers in the database. Users can
select one or more experiment and click the ‘view miRNAs’ button to view the miRNA list. (E) miRNA page. This page mainly consists of four sections:
miRNA Summary, Expression Profile and Expression Detail and Validation.
that aberrant expression of miRNAs plays a critical role
in human cancers (30). The decreasing cost of the high-
throughput methods has led to large amount of miRNA
transcriptome data from cancer-related studies. This allows
researchers to perform miRNA quantification analysis in
cancer samples and identify cancer associated miRNAs.
Here, we provide the dbDEMC 2.0 to utilize these resources
and to provide a tool to facilitate the study of miRNA ex-
pression levels in cancer.
dbDEPC 2.0 now has documented much more datasets
and differentially expressed miRNAs than the first version
(Supplementary Figure S2). In addition to a greater num-
ber of miRNA–cancer associations included, dbDEMC 2.0
also has several advanced features that distinguish it from
other sources. For instance, by studying the samples profiled
in each of the collected data sets, we defined seven classes of
differential expression analyses relevant to the processes of
neoplastic transformation and progression. These included
cancer versus respective normal tissue, high grade versus
low grade samples, metastasis versus primary cancer, sub-
type1 versus subtype2, poor outcome versus good outcome,
blood samples from cancer patient versus blood samples
from normal person, and also drug-treatment samples ver-
sus non-treatment samples. This approach provides a bet-
ter way in application yet robust to the heterogeneous data
formats and experimental designs for miRNA expression.
For instance, circulating miRNAs have been one of the hot
topics in cancer research, it has been suggested as an impor-
tant class of potentially promising biomarkers in a variety
of different cancers (31,32). Users can query the database by
different cancer types and then filter the associated exper-
imental design easily to check the differentially expressed
miRNA list.
By analysing the data from database, we could find im-
portant miRNAs that may drive cancer development. Pre-
vious studies have shown many miRNAs present consistent
differential expression pattern across cancer types. These
miRNAs can cooperatively regulate oncogenic pathways
and contribute to cancer hallmarks (33,34). We would like
to re-assess this using the result in the database. Here,
we only focus on the data from TCGA as it used high-
quality miRNA-Seq method and avoid the heterogeneity
from different miRNA expression platforms. We selected
twelve cancer types with sufficient samples profiled, miR-
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Figure 3. Meta-proofing tool and Venn-diagrams. (A) Meta-profiling page. Users can input a list of miRNAs, select particular cancer type and pick one
type of experimental design to generate a differential expression heatmap. (B) An example heatmap visualize the miRNA differential expression profiles
in multiple cancer types focus on cancer versus normal comparison. (C) Overlap of the miRNAs among dbDEMC 2.0 and other three external databases.
(D) Overlap of the cancer types among dbDEMC 2.0 and other three external databases.
NAs present consistent up- or down-regulation across all
or most cancer types are of particular interest, since these
may represent candidate list of oncogenes or tumor suppres-
sors. We identified a list of 42 miRNAs which were consis-
tently deregulated across at least nine of the twelve cancer
types, with 25 of these upregulated, and with the remaining
17 exhibiting downregulation (Supplementary Figure S3).
Among the deregulated miRNAs, many have been previ-
ously demonstrated to be associated with cancers. For in-
stance, miR-23b could function as a tumor suppressor that
present downregulation in stomach cancer (35) and bladder
cancer (36). Whereas the miR-130 family have been iden-
tified as upregulated in many cancer types that represent-
ing putative oncogene (37,38). This pan-cancer wide meta-
profiling analysis indicated that the comprehensive investi-
gation of the database may help to illuminate the compli-
cated relationship between miRNAs and cancers and de-
velop more effective treatment strategies for cancers.
In summary, dbDEMC 2.0 provides a comprehensive
collection of cancer related miRNAs based on analysis of
large scale expression profiling data. As the cancer related
miRNA expression profiling data accumulate rapidly, this
database will be updated periodically to incorporate new
miRNA expression data. We hope to make dbDEMC 2.0
a useful resource that facilitate to cancer research, and con-
tribute to the biomarker discovery or even cancer treatment
related to miRNA.
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